Taysha Gene Therapies EBITDA 2020-2024 | TSHA
Taysha Gene Therapies ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Taysha Gene Therapies Annual EBITDA
(Millions of US $) |
| 2023 |
$-71 |
| 2022 |
$-161 |
| 2021 |
$-173 |
| 2020 |
$-43 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$-26 |
| 2024-06-30 |
$-21 |
| 2024-03-31 |
$-24 |
| 2023-12-31 |
$-16 |
| 2023-09-30 |
$-16 |
| 2023-06-30 |
$-23 |
| 2023-03-31 |
$-16 |
| 2022-12-31 |
$-56 |
| 2022-09-30 |
$-25 |
| 2022-06-30 |
$-33 |
| 2022-03-31 |
$-49 |
| 2021-12-31 |
$-50 |
| 2021-09-30 |
$-51 |
| 2021-06-30 |
$-41 |
| 2021-03-31 |
$-32 |
| 2020-12-31 |
$-18 |
| 2020-09-30 |
$-15 |
| 2020-06-30 |
$-4 |
| 2020-03-31 |
$-6 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.506B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
